Q-omics provides the consensus-scored FTLP3 profile across patient tissues and cancer cell-line models. FTLP3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FTLP3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, FTLP3 RNA expression shows 15,687 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight CESC, HNSC, and SARC as cancer lineages where FTLP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP3 survival associations across molecular data types. FTLP3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP3 RNA expression–survival associations across cancer types. High FTLP3 expression shows unfavorable associations in UVM, MESO, LIHC, LGG and BRCA, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for FTLP3 RNA expression.
This table summarizes FTLP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP3 shows lower tumor expression in LUSC and higher tumor expression in HNSC, COAD, KIRC, LIHC and STAD. The HNSC box plot shows higher FTLP3 RNA expression in tumor versus normal tissue (log2 FC = +1.143, t-test p < 0.001).
This table shows molecular features associated with FTLP3 in patient tissues and cancer cell lines. In patient samples, FTLP3 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
